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Background: Recently, a new subset of T helper (Th) cell that predominantly secret cytokine interleukin-22 (IL-22) is
identified, termed Th22 cells. The Th22 subset has been demonstrated to be involved in immunity and tissue
inflammation. However, the existence of Th22 cells and role of IL-22 in acute viral myocarditis (AVMC) remain
unknown.
Methods: BALB/c mice were intraperitoneally (i.p) infected with CVB3 for establishing AVMC models. Control mice
were treated with phosphate-buffered saline (PBS) i.p. On day 14 post injection, frequencies of splenic Th22 cells
were determined, productions of IL-22 and expressions of IL-22R (IL-22 receptor) were measured. To further
investigate the effects of IL-22, AVMC mice treated with Anti-IL-22 neutralizing antibody were explored. The severity
of AVMC were monitored; the frequencies of Th22 cells, the expressions of IL-22 and IL-22R were investigated; in
addition to IFN-γ, inflammatory cytokines IL-17, TNF-α, IL-6 as well as IL-1β, were evaluated. Cardiac viral replication
were detected.
Results: Compared with control group, significant elevations of circulating Th22 cells and IL-22, cardiac protein and
mRNA of IL-22, and IL-22R1 were demonstrated in AVMC group. Treatment of AVMC mice with Anti-IL-22 Ab
exacerbated the severity of viral myocarditis, verified by lower survival rate, higher HW/BW ratios and cardiac
pathological scores. Anti-IL-22 Ab decreased the frequencies of Th22 cells and the levels of IL-22, and increased the
expressions of cardiac IL-22R1. Up-regulations of IL-17, IL-6 and TNF-α, down-regulations of IFN-γ proteins and gene
expressions in the plasma and myocardium, were observed in Anti-IL-22 Ab group. Furthermore, neutralization of
IL-22 significantly promoted cardiac viral replication.
Conclusions: Our data indicate that the increased frequencies of IL-22-producing Th22 cells may play an important
role in the pathogenesis of CVB3-induced mice AVMC, IL-22 may act as an myocardium-protective cytokine via the
IL-22–IL-22R pathway, and suggest that targeting the Th22 cell and IL-22–IL-22R pathway could provide new
therapeutic modalities for the treatment of CVB3-induced AVMC.
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Acute viral myocarditis (AVMC) is characterized by myo-
cardial inflammation and can progress to chronic dilated
cardiomyopathy (DCM), a terminal condition requiring
transplantation. Coxsackievirus B (CVB), an enterovirus
of the Picornaviridae family, its infection is surprisingly
prevalent, with an estimated 70% of the human population
having exposed to these viruses. CVB3, a member of the
CVB group, is the primary pathogen of viral myocarditis
[1]. Accumulating data had indicated the dominant cause
of myocardial cells damage in AVMC were inflammation
and autoimmune responses triggered by the viral infec-
tion, mediated by T cells and their cytokines [1-3]. Emer-
ging evidence have demonstrated that several Th subsets,
such as Th1, Treg, Th17 but not Th9 cells, are involved in
the pathogenesis of AVMC [4-8]. But the fundamental
mechanisms responsible for AVMC are not completely
clarified, and therapeutics for AVMC are restricted to sup-
portive care including basic medications [9].
Recently, the Th22 cell has been recognized as a novel
Th cell subset, which is characterized by abundant produc-
tion of IL-22 but not IL-17 or IFN-γ [10-12]. This newly
identified CD4+T cells clones have low or undetectable ex-
pression of transcription factor T-bet and RORγt (Th1 and
Th17). With the CCR6+CCR4+CCR10+ phenotype, aryl
hydrocarbon receptor (AHR) has been considered to be
the key transcription factor of Th22 subset. Driven by the
combined effects of IL-6 and TNF-a, naïve T cells differen-
tiate toward the Th22 phenotype in human [10]. All of
above evidence strongly support that the Th22 cell repre-
sent a terminally differentiated and independent T cells
subtype. Demonstrated by emerging literature in kinds of
diseases such as rheumatoid arthritis, atopic dermatitis,
systemic sclerosis, human immunodeficiency virus (HIV)
infection, Th22 cells were considered providing a unique
contribution to tissue inflammation, virus infection and
immune responses [13-16].
IL-22, the crucial Th22 signature cytokine, its role had
been demonstrated by developing literatures, which reported
that neutralization or genetic deletion of IL-22 could alleviate
or exacerbate the severity of kinds diseases such as antigen-
induced airway inflammation and T cell-mediated hepatitis
[17,18], indicating that targeting IL-22 might represent a
promising novel therapeutic approach for acute-phase re-
sponse, immunity and inflammation. IL-22 mediates its
effects via IL-22R, a heterodimeric transmembrane receptor
complex consisting of IL-10R2 and tissue-specific IL-22R1
[19]. IL-10R2 is ubiquitously expressed, while the expression
of IL-22R1 is restricted to nonhematopoietic cells. Signaling
through IL-22R1 is restricted to IL-22, and tissues that lack
IL-22R1 will not be a target for IL-22 under currently known
molecular pathways. An increasing number of human-and
mouse-based studies have indicated that IL-22–IL-22R inter-
actions can modulate the expressions of considerable genessuch as IL-17,IFN-γ,IL-1β,TNF-α,IL-6, and highlighted the
fact that IL-22–IL-22R interactions are an integral pathway
through which cells of the innate and adaptive immune
responses regulate immunity and inflammation [20-22].
The existence of Th22 cells in CVB3-induced mice
AVMC is still unclear. The roles of both IL-22 and the
IL-22–IL-22R pathway in the pathogenesis of AVMC re-
main to be clarified. Therefore, our present study exam-
ined the frequencies of Th22 cells, investigated the
expressions of IL-22 and IL-22R, targeted of IL-22 in vivo
in mice AVMC with the use of neutralizing Anti-IL-22
antibodies, and aimed to preliminary explore the presence
of Th22 cells and functional characteristics of IL-22 in
AVMC.
Results
Evaluation for the severity of AVMC
The signs of AVMC were apparent in the AVMC group,
including weakness, coat ruffling, irritability, back arching,
lethargy, anorexia and weight loss. The cardiac patho-
logical scores of AVMC were dramatically increased on
day 14 post infection (2.6 ± 0.4). In contrast, the patho-
logical scores of heart sections in the control group was 0,
as neither inflammatory cell infiltration or necrosis lesion
was observed (Figure 1A, p<0.05). On day 14 post injec-
tion, 5 of 20 mice died in the AVMC group. Specifically,
on day 7,8,10,11 post infection, there were 1,1,2,1 mice
dead in the AVMC group. Contrary, 0 of 12 mice died in
the control group. Statistical differences were observed
when comparing the survive rate of AVMC with control
(p<0.05).
Elevated expressions of IL-22 and IL-22R in AVMC
On day 14 post infection, compared with those in control
mice treated with PBS only, much higher levels of the IL-22
protein and gene transcripts were detected in myocardium
in AVMC mice, respectively (236.24 ± 43.26 vs. 17.45 ±
5.21, 21.28 ± 4.28 vs. 4.28 ± 0.97, both p<0.01, Figure 1B,C
and E). As shown in Figure 1D, the significantly increased
level of the circulating IL-22 protein in the AVMC group
was observed compared with that in the control group
(20.21 ± 3.81 vs. 3.02 ± 0.83pg/ml, p<0.01). Meanwhile, the
relative cardiac gene expression of IL-22R1, the specific re-
ceptor of IL-22, was obviously up-regulated in the AVMC
group, compared with that in the control group (3.01 ± 0.78
vs. 1.05 ± 0.29, p<0.01). In contrast, the relative cardiac tran-
scripts of IL-10R2 in the AVMC group were less than those
in the control group (43.28 ± 9.14 vs. 58.5 ± 9.01, p<0.05).
Increased proportions of Th22, Th17 and Th1 cells in
AVMC
Flow cytometry experiments were performed on mono-
nuclear cells from spleen with gating on CD4+, on day 14
post injection. We detected Th22, Th17 and Th1 cells in
Figure 1 Elevated expressions of IL-22 and IL-22R in AVMC, on day 14 post infection. A. Representative of myocardial histopathologic
images in AVMC and control groups (H&E, original magnification × 400). B. Representative of IL-22 immunohistochemistry images in heart tissue
(Dark brown granules, original magnification × 400). C. Morphometric quantitation of cardiac IL-22 protein expressions. D. ELISA analysis of IL-22
protein levels in the plasma. E. Relative cardiac expressions of IL-22–IL-22 receptor complex gene were detected by RT-PCR. *p < 0.05, **p < 0.01.
Data are mean ± SD. AVMC, Acute Viral Myocarditis.
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Figure 2C, the percentage of the pure Th22 cell (IL-22+
IL-17-IFN-γ-CD4+) represented a higher value in the AVMC
group (3.47 ± 0.66%), showing a significant increase in com-
parison with that in the control group (0.84 ± 0.33%,
p<0.01). Meanwhile, the percentage of Th17 cells in the
AVMC group was distinctly higher than that in the control
group (2.41 ± 0.55% vs. 0.81 ± 0.33%, p<0.01). Similarly, the
significantly increased level of the Th1 cell was observed in
AVMC (7.89 ± 2.01%) compared with that in the control
group (3.32 ± 0.79%, p<0.01, Figure 2C). It was established
that the numbers of Th22 cells in the AVMC group were
correlated positively with the numbers of Th17 and Th1
cells (both p<0.05, Figure 2D).Neutralization of IL-22 exacerbated the severity of AVMC
As shown in Figure 3, the results showed that Anti-
IL-22Ab accelerated the development of myocarditis and
exacerbated the severity. Firstly, the number of mice
surviving to 14 day was 5, 10 and 10 for Anti-IL-22 Ab,
IgG control and PBS groups, respectively. The survival
rate of the Anti-IL-22 group was significantly decreased
compared with those in IgG control and PBS groups
(Figure 3B, both p<0.05). Consistently, both the patho-
logical scores of heart sections and the values of HW/
BW in mice receiving Anti-IL-22Ab were higher than
those in PBS and IgG control groups (Figure 3C-D, all
p<0.05), on day 14 post infection. Regarding the survival
rates, ratios of HW/BW and cardiac pathological scores,
no significant differences were observed between PBS
and IgG control groups (all p>0.05).Neutralization of IL-22 decreased the percentage of the
Th22 cell and dysregulated the expressions of the
IL-22–IL-22R pathway
As shown in Figure 4A, the alterations of Th22 cells in
Anti-IL-22 Ab, IgG control and PBS groups were investi-
gated by flow cytometry, on day 14 post infection. The per-
centage of Th22 cells in the Anti-IL-22 Ab group was less
than those in IgG control and PBS groups (both p<0.05).
No significant difference was observed between PBS and
IgG control groups (p>0.05). The effects of Anti-IL-22 Ab
on the expressions of the IL-22–IL-22R pathway were fur-
ther addressed. Compared with those in IgG control and
PBS groups, marked reduction of the circulating level of the
IL-22 protein was detected in the Anti-IL-22 Ab group
(Figure 4B, both p<0.01). As shown in Figure 4C and D,
higher levels of the IL-22 protein and gene expression in
myocardium lesions were observed in the Anti-IL-22 Ab
group (all p<0.05). Regarding the levels of the IL-22 protein
and transcripts, no significant differences were observed be-
tween PBS and IgG control groups (all p>0.05). At the same
time, compared with those in PBS and IgG control groups,
the level of cardiac IL-22R1 mRNA was increased signifi-
cantly after IL-22 neutralization (both p<0.05, Figure 4D).
The level of IL-22R1 did not exhibit distinct difference be-
tween IgG control and PBS groups. In contrast, IL-10R2
gene expressions were comparable among the Anti-IL-22
Ab, IgG control and PBS groups (all p>0.05).
Neutralization of IL-22 increased the productions of IL-17,
TNF-α and IL-6, decreased the level of IFN-γ
On day 14 post injection, the cardiac mRNA expressions
of inflammation cytokines such as TNF-α, IL-17A, IL-6,
Figure 2 Increased proportions of Th22, Th17 and Th1 cells in AVMC were investigated by flow cytometry analysis, on day 14 post
injection. A.Th22 cells within CD4+T cells were identified based on their expressions of IL-22+IL-17-IFN-γ-CD4+. B.Th17 and Th1 cells within CD4+T
cells were determined based on their expressions of IL17+CD4+ and IFN-γ+CD4+. C. Comparisons of Th22, Th17 and Th1 cells in AVMC and
control groups. D. The correlation analysis of Th22 and Th17, Th22 and Th1 cells in AVMC group. Each point represented an individual mouse. **p
< 0.01. Data are mean ± SD.
Figure 3 Neutralization of IL-22 exacerbated the severity of AVMC on day 14 after infection. A. Representative of myocardial
histopathologic images in Anti-IL-22 Ab,IgG control and PBS groups (H&E, original magnification × 400). B. Survival rate was significantly
decreased in Anti-IL-22 Ab group. C. The pathological scores in different groups. Each point represented an individual mouse. D. The ratios of
HW/BW in different groups. *p< 0.05.
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Figure 4 Neutralization of IL-22 decreased the percentage of the Th22 cell, dysregulated the expressions of IL-22–IL-22R pathway on
day 14 post infection. A. The result of statistical analysis for the alterations of Th22 cells in Anti-IL-22 Ab,IgG control and PBS groups,
investigated by flow cytometry. B. The levels of plasma IL-22 were measured by ELISA. C. Morphometric quantitation of cardiac IL-22 protein
expressions were explored by IHC. D. Relative cardiac expressions of IL-22/IL-22 receptor complex gene were detected by RT-PCR. *p < 0.05, **p < 0.01.
Data are mean ± SD.
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over, their protein productions in plasma were measured
by ELISA. As shown in Figure 5A-C, compared with
those in PBS and IgG control groups, the levels of IL-
17A,TNF-α and IL-6 mRNA and proteins were increased
dramatically in the Anti-IL-22 Ab group (p<0.01 or p<0.05).
These levels did not show significant differences between
PBS and IgG control groups (all p>0.05). However, the
expressions of the IFN-γ mRNA and protein in the Anti-IL-
22 Ab group were lower than those in PBS and IgG control
groups (Figure 5D, all p<0.05), and no significant difference
was detected between PBS and IgG control groups (p>0.05).
No significant changes in the levels of the IL-1β transcripts
and protein were observed among Anti-IL-22 Ab, PBS and
IgG control groups (Figure 5E, all p>0.05).
Neutralization of IL-22 promoted viral replication
Compared with those in PBS and IgG control groups,
the levels of cardiac CVB3 RNA and CVB3 titers in the
Anti-IL-22 Ab group were elevated markedly, indicated
by RT-PCR and plaque-forming unit (PFU) experiments
(Figure 5F, all p<0.01). However, no obvious differences
in these levels were observed between PBS and IgG con-
trol groups (p>0.05).
Discussion
There is growing evidence that T cell activation and its
cytokine expression play a key role in the pathogenesis
of CVB3-induced AVMC, such as IFN-γ-producing Th1
cells and IL-17-producing Th17 cells [4-7]. Recently,several works related to Th22 cells have broadened our
understanding of T cell-mediated tissue inflammation
and immunity [13-16]. Pure Th22 cells represents a dis-
tinct CD4+T cell subset characterizing by the secretion
of IL-22, but not IL-17 or IFN-γ, thus is identified as IL-
22+IL-17-IFN-γ-CD4+T cells [10-12,16]. IL-22, the cru-
cial cytokine of Th22 cells, mediates its effects via IL-
22R and propagates downstream signals including JAK/
STAT, ERK, JNK, PI-3K and p38 MAP kinase pathways
[19,23,24]. A considerable amount of data indicated that
the Th22 cell and its crucial cytokine IL-22 could exert
either pro-inflammatory or anti-inflammatory activities
depending on the context [13-18,22]. In the present
work, we tried to exploit the potential that Th22 cells
may participate in the inflammatory and immune re-
sponse in AVMC. As excepted, higher percentage of the
Th22 cell was observed in CVB3-induced mice AVMC,
similarly to those of Th17 and Th1 cells. Our data uncov-
ered the evidence of significant elevations in circulating
Th22 cells and IL-22 proteins, cardiac mRNA and protein
expressions of IL-22 in AVMC. It seems that infective and
immunity microenvironment of AVMC is suitable for the
differentiation and proliferation of Th22 cells. These novel
findings confirm an individual signature for the IL-22-
producing Th22 subset in AVMC, and provide a cellular
target for therapeutic intervention and may also shed light
on thus far unknown pathways in the control of AVMC.
Based on the observation that levels of IL-22 and IL-22
receptor were elevated in AVMC, we examined the efficacy
of IL-22 in the AVMC mouse model, with the use of anti-
Figure 5 Neutralization of IL-22 increased the productions of IL-17, TNF-α and IL-6, decreased the level of IFN-γ, promoted cardiac
viral replication on day 14 post infection. Relative cardiac expressions of IL-17, TNF-α, IL-6, IFN-γ and IL-1β were investigated by RT-PCR, and
the levels of their circulating protein were measured by ELISA in Anti-IL-22 Ab, IgG control and PBS groups. A-E: IL-17, IL-6, TNF-α, IFN-γ and
IL-1β, respectivity. F. The cardiac CVB3 titers and relative expressions of CVB3 RNA were investigated by PFU and RT-PCR. *p < 0.05, **p < 0.01. Data
are mean ± SD.
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in human or murine model systems have indicated that IL-
22 could be either pathologic or protective, depending on
the context in which it was expressed [17,18,22,26,27]. Our
results proved that neutralization of IL-22 exacerbated the
severity of AVMC, which was verified by the lower survive
rate, higher values of HW/BW and pathological scores of
heart sections. Meanwhile, down-regulations of circulating
Th22 cells and IL-22 were observed in the Anti-IL-22Ab
group. The Th22 cell is not the unique source of IL-22.
However, Both the pathogenic effect of Anti-IL-22 Ab in
our AVMC model and protective role of the IL-22-Ig fu-
sion gene in experimental autoimmune myocarditis (EAM)
model [28], suggest that this cytokine has an important
myocardium-protective role regardless of the cell source.
Emerging literature indicate that IL-22 participates in
immunity and tissue inflammation through the IL-22–IL-
22R pathway [20,22]. To explore the role of this pathway
in AVMC, we firstly investigated the expressions of car-
diac IL-22 and IL-22R, the latter which consists of IL-
22R1 and IL-10R2. Because signaling through IL-22R1 isrestricted to IL-22, we focused on IL-22 and IL-22R1 [22].
Compared with IL-22 and IL-22R1, dramatically higher
relative cardiac expression of IL-10R2 was detected in
mice, consistence with previous data that IL-10R2 was
highly expressed [20,22]. Compared with those in the con-
trol group, significant elevations of IL-22 and IL-22R1
were identified in the AVMC group. Although the major
IL-22-producer are immune cells, it has been confirmed
that IL-22R1 expression is absent on immune cells but in-
stead restricted to tissues, thus IL-22 acts as a middle-
men between the immune system and its environment
[22]. These increases of cardiac IL-22 and IL-22R1 may
strengthen signaling directionality from the immune sys-
tem to myocardium, and are thus involved with the pat-
hogenesis of AVMC. After IL-22 was blockade with a
neutralizing antibody in AVMC, down-regulations of IL-
22 and up-regulations of IL-22R1 were observed. These
data are consistent with a previous study that IL-22R1 ex-
pression was decreased after treatment with rIL-22 but
increased after IL-22 neutralization, while IL-10R2 was
not changed significantly in liver ischemia-reperfusion
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may be explained by the following mechanism: IL-22R1
has been recognized as a driver of inflammation, and has
a autoregulatory feedback loop that amplifies the level of
IL-22 [29,30]. When IL-22 is decreased by neutralization
of anti-IL-22 Ab, IL–22R1 may be increased by autoregu-
latory feedback loop that promotes the levels of IL-22.
And the promotion of IL-22R1 further aggravates the
myocarditis in the anti-IL-22 group. On the other hand,
IL-10R2 is constitutively expressed on virtually all cells
types at high levels and is an component of the receptor
complexes for IL-22, IL-10, IL-26, IL-28, and IL-29, thus
the effect of anti-IL-22 on the expression of IL-10R2 is
not significant. Further investigation with the use of heart-
specific IL-22 transgenic mice and mice that lack IL-22R1
will be of particular interest to clarify the dysregulation of
the IL-22–IL-22R pathway in AVMC.
Our data suggest that dysregulated IL-22–IL-22R signal
can modulate expressions of considerable genes and regu-
late the productions of inflammatory cytokines, verified by
the fact that IL-22 neutralization significantly promoted
the circulating and cardiac IL-17, IL-6, TNF-α, which have
been identified as important pro-inflammatory cytokines
and exacerbating myocarditis by inflammation and im-
munity [4,5]. More specifically, dysregulated IL-22–IL-
22R pathway in the Anti-IL-22 Ab group contributed to
cardiac viral replication, and decreased the level of IFN-γ,
which was considered as the vital defenders against viral
infection [28,31]. Our data was consistent with the previ-
ous observation that IL-22 contributed to resistance to
viral infection [32], highlighting a role for IL-22-producing
Th22 cells in controlling cardiac viral replication in
AVMC. It seems whether IL-22 response modulates the
expression of IL-1β is context dependent because no sig-
nificant change of IL-1β production was observed in the
Anti-IL-22 Ab group [20,33,34].
To our knowledge, this is the first demonstration that
Th22 and IL-22–IL-22R pathway may participate in the
development of AVMC but with several limitations. First,
the neutralization of IL-22 antibody biological activity was
not fully quantified, and we have not addressed the mech-
anism responsible for proliferation of Th22 cells in mice.
Whether the decreased Th22 cells in the anti-IL-22Ab
group was due to the ab neutralizing or impaired prolif-
eration, required future study. Second, Th22 has been
regarded as the most important IL-22-producing CD4+T
cells (71.9%) [16], elucidation of the role of the IL-22–IL-
22R pathway would be helpful to understand the whole
picture of Th22 cells-involved in AVMC. However, the
source of IL-22 was not limited by the Th22 cell. NKT,
Th17, Tc17, innate-like γδT, even in Rag2−/− mice which
lack of T cells, are IL-22 producers in mice [22,35]. Thus
the myocardium-protective role of IL-22 could not be
used to absolutely identify the Th22 function. In futurestudies on transcription factor AHR, chemokine receptor
CCR6, PI-3 kinase pathway based-screening, will be of
benefit to understanding of the Th22 cell regulation dur-
ing inflammatory responses in AVMC [23,24]. Further-
more, whether RORC reflects the capacity to produce
IL-17 and IL-22 in AVMC, is an interesting open issue.Conclusions
In summary, our preliminary data demonstrate that
enriched IL-22-producing Th22 cells represent a distinct
T cell subset in CVB3-induced mice AVMC. IL-22 may
play a myocardium-protective role through the IL-22–IL-
22R pathway in AVMC. Further studies focusing on the
differentiation, regulation, downstream pathways of IL-22-
producing Th22 cells, especially in human systems, are
required to comprehensively explore the therapeutic po-
tential of Th22 cells in AVMC.Methods
Mice
Specific pathogen-free male BALB/c mice aged 6 week
were purchased from the Hunan Laboratory Animal
Centre, Chinese Academy of Sciences, Hunan, China
(Certificate No. SCXK (Xiang) 2009–0004). All animals
were kept in the pathogen-free mouse room in the ex-
perimental animal center (Experimental Animal Center
of the Guangxi Medical University, Nanning,China), and
all experiments were carried out in accordance with pro-
tocols approved by Guangxi Medical University Animal
Ethics Committee.Virus
The CVB3 (Nancy strain, from Institute of immunology
of Guangxi Medical University) was maintained by pas-
sage through Hep-2 cells. The virus titer determined by
PFU assay was 1×108. The CVB3 was diluted in PBS
(Solarbio Science & Technology Co, Ltd, Beijing, China).
BALB/c mice were infected by an intraperitoneally injec-
tion (i.p) of 100 μl PBS containing approximately 106
PFUs of the virus for establishing AVMC models.Induction of AVMC
A total of 32 mice were randomly divided into two groups:
1) in the AVMC group, BALB/c mice were treated with
CVB3 (100 μl per mouse) i.p. (n = 20); 2) mice administered
i.p. with PBS were taken as control (n = 12). The day when
mice were injected i.p. was defined as day 0. All surviving
animals were sacrificed on day 14 after infection. Hearts and
spleens were removed aseptically as fresh specimens to be
measured, blood was harvested and the plasma was prepared
for study.
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For in vivo IL-22 neutralization, a total of 36 mice which
infected with CVB3 (AVMC mice) were randomly divided
into three groups: administered either Anti-IL-22 Ab (50 μg
per mouse; R&D Systems, Inc. Minneapolis, MN.AF582;
n=12,Anti-IL-22Ab group); an normal IgG control (50 μg
per mouse; R&D Systems,Inc. Minneapolis,MN.AB-108-C;
n=12, IgG control group); or PBS (n=12, 50 μg per mouse;
PBS group) i.p., at day 0. All surviving animals were sacri-
ficed on day 14 after CVB3 infection. The survival rates and
values of the heart weight/body weight (HW/BW) were
recorded. The hearts, spleens and plasma were collected.
Histopathology
The ventricular tissues of the hearts were fixed in 10% for-
malin, then embedded in paraffin. After sectioned along
the entire length of the heart into 5-μm sections, and
stained with H&E (hematoxylin and eosin), histopatho-
logical change was observed by using light microscopy
(Nikon Eclipse E800 Microscope, Kawasaki, Kanagawa,
Japan). Pathological scores were graded by two independ-
ent pathologists separately in a blinded manner based on
the following semi-quantitative scale: 0, no inflammatory
infiltrates; 1, small foci of inflammatory cells between
myocytes or inflammatory cells surrounding individual
myocytes; 2, larger foci of 100 inflammatory cells or in-
volving at least 30 myocytes; 3, 10% of a myocardial cross-
section involved; 4, 30% of a myocardial cross-section
involved [3].
Flow cytometry
Spleens from mice were collected aseptically. After min-
cing, splenic cells were gently dispersed through nylon
mesh into a single-cell suspension. Then these splenic
mononuclear cell suspension was washed with RPMI
1640 (Gibco, USA). The lymphocyte fractions of these
samples were obtained by Ficoll-Plaque (Solarbio Sci-
ence & Technology, China) gradient centrifugation.
Then cells were resuspended in RPMI 1640 medium
with 10% FCS (Gibco, USA), stimulated with phorbol
myristate acetate (PMA, 25ng/ml, Sigma- Aldrich, USA)
and ionomycin (1μg/ml, Sigma-Aldrich) in the presence
of GolgiPlug(1 ul/106cells, BD Biosciences) at 37°C, 5%
CO2 of a 24-well culture plate. After 4h incubation, the
cells were harvested and stained with phycoerythrin
Cye-5- conjugated anti-mouse CD4 (PE-Cye-CD4, BD
Biosciences). Then cells were stained intracellularly with
anti–IL-22, –IL-17, or –IFN-γ mAb conjugated with
APC, PE, or AF488(Alexa-FluorW488)after fixation and
permeabilization (BD Biosciences, eBioscience), analyzed
on a FACS-Calibur flow cytometer (BD Bioscience). Cell
Quest soft-ware (BD Biosciences) was used for data ac-
quisition. Pure Th22 cells were defined as IL-22+IL-17-
IFN-γ-CD4+.Immunohistochemistry
Immunohistochemical staining was performed by the
streptavidin-biotin complex method according to the
manufacturer’s instructions. Rabbit polyclonal antibodies
against mouse IL-22 (Abcam, USA) at a 1:200 dilution
were used as primary antibodies. The sections were washed
and stained using the streptavidin-biotin complex kit
(Boster, Wuhan, China). After the sections were rehydrated,
endogenous peroxidase activity was blocked with 3% hydro-
gen peroxide for 10 min at room temperature. Then the sec-
tions were first incubated in 5% bovine serum albumin for
20 min and then in the primary antibody for 24h at 4°C,
and incubated with the streptavidin-biotin complex for 20
min. At last, the sections were developed with 3,3-diamino-
benzidine (Boster, Wuhan, China) and observed under a
light microscope. Instead of primary antibody, non-immune
goat serum was taken as a control. IL-22 deposition in the
cytoplasm and cytomembrane of myocardium were evalu-
ated semi-quantitatively according to the extent and inten-
sity of staining using Image-Pro Plus Version 6.0 (Media
Cybernetics, Bethesda, MD). 5 fields from each slice were
randomly selected by two pathology experts, who were un-
aware of the groups and evaluated by integrated optical
density (IOD).
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Viral titers were determined by standard plaque formation
assay. After part of the heart was weighed and homogenized
in 2 ml PBS, three freeze-thaw cycles and centrifuging at
2000 rpm for 10 min were undertaken, then supernatant
was sequential 10-diluted in RPMI 1640 medium. The HeLa
cell monolayers were incubated with the supernatant for 1 h
at 37°C, 5% CO2, in six-well plates, washed in PBS, and cov-
ered with 2 ml 0.4%agar, DMEM, and 5%FCS. After 72 h of
cultivation, the monolayers were fixed in para formaldehyde
and stained in crystal violet, and the numbers of plaques
were counted. Viral titers were expressed per organ weight
(in grams).
Real-time RT-PCR
The total RNA of homogenized heart tissues was
extracted with TRIZOL ReagentW (Invitrogen,USA), and
then reverse transcripted into cDNA with an Reverse
Transcription kit (Ferma, CA) according to the manufac-
turer’s instructions. Primers for IL-22,IL-22R1,IL-10R2,IL-
17A,IFN-γ,IL-1β,TNF-α,IL-6, CVB3,and the housekeeping
gene β-actin are designed by Primer Premier 5.0 (Table 1).
Real time-polymerase chain reaction (RT-PCR) was per-
formed using an ABI 7500 Sequence Detection System
(Applied Biosystems, Foster City, CA) using SYBR green.
After an initial denaturation step for 3 min at 94°C, a
three-step cycling procedure (denaturation at 94°C for 30
sec, annealing at 60°C for 30 sec, and extension at 72°C
for 60 sec) was used for 35 cycles. The relative gene
expressions were normalized to the level of β-actin tran-
scripts and quantified by the △△CT method using 7500
System Sequence Detection software (Applied Biosys-
tems). All reactions were performed in at least duplicate
for each sample.
Cytokine assay
Cytokine content was determined by enzyme-linked im-
munosorbent assays on plasma. The amounts of IL-22
were detected using the Quantikine Mouse IL-22 Im-
munoassay (Biolegend,Cat.No.436307,USA). The levels
of IL-17A,IFN-γ, IL-1β,TNF-α,IL-6 in mice were deter-
mined by ELISA kits (Shanghai ExCell Biology Inc.
China), according to the manufacturer’s instructions.
The sensitivity of ELISA kits for IL-22,IL-17,IFN-γ,IL-1β,
TNF-α,IL-6 was 5,7,7,7,4 and 7pg/ml, respectively, and
no cross-reactivity was observed in detection. All sam-
ples were measured in triplicate.
Statistical analysis
Statistical analyses of data were performed with one-way
ANOVA. Correlations were determined by Spearman
rank correlation coefficients. Survival was estimated by
the Kaplan-Meier method and compared by the log-rank
test. The differences between pathological scores wereevaluated using the Mann–Whitney U test. All data were
analyzed with SPSS 17.0. Differences were deemed to be
statistically significant at p<0.05.
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